Best of ESMO24
The ESMO Congress 2024 took place in Barcelona, from September 13 to 17, 2024, at the Fira Barcelona Gran Via.
This significant event, organized by the European Society for Medical Oncology (ESMO), attracted over 30,000 participants, including healthcare professionals, researchers, patient advocates, and industry representatives from around the globe.
The congress featured nearly 300 sessions, presenting over 2,000 abstracts, with a focus on the latest advancements in cancer research and treatment. Key topics included new therapeutic combinations for various cancers, the long-term effects of immunotherapy, and innovative approaches integrating artificial intelligence into cancer care.
Here are some highlights from ESMO24:
“ESMO24 Lung Orals.
Super presentation by Benjamin Besse on mechanisms of acquired resistance to ami/laz in EGFR+ NSCLC shows potentially less RB1 loss/sclc transformation A clinically relevant outcome if confirmed clinically, one to watch.”
“Treatment landscape for EGFR lung cancer is getting more complex – for clinicians and patients. But as Dr Jurgen Wolf says at ESMO24 ‘Always good to have several arrows in your quiver.’
Absolutely agree. Stratifying which patients are best for which option is key.”
“Gene signatures have revolutionized treatment for HR+ eBC. Could they also refine treatment for more aggressive subtypes? Intriguing data of TNBC-DX from a pooled analysis of 418 patients treated with neoadjuvant taxane-based chemo.”
“Thanks to the entire team of our French thoracic oncology group IFCT (and investigators) for successfully conducting this clinical trial in BRAFV600E mutated NSCLC patients, presented this morning in an oral session at ESMO! A new therapeutic option for our patients…”
“Young talent Manon de Graaf from The Netherlands Cancer Institute, Marleen Kok Lab presenting data on patients with stage 1 TNBC. Good registries thanks to IKNL allow for analysis of populations excluded from most trials!”
“ESMO24 Lung Orals.
Provocative questions:
- Corey Langer ‘is RB1 loss on cfDNA indicative of clinical sclc transformation?’
- Tony Mok ‘does LaG3+ correlate with response to nivo-rel’
- David Gandara ‘methylation may matter in EGFR+ acq resistance’”
“Long awaited results of the first phase II randomized trial evaluating a ct-DNA guided rechallenge strategy with Cet+Iri (CITRIC)
ORR 0% vs 9.7%
DCR 44.4% vs 74.2%
Another piece of the puzzle waiting for the ongoing PARERE trial by GONO Foundation.”
“New data for intermediate HCC at ESMO24 from LEAP-012 trial
PFS/ORR benefit for LenvaPembro+TACE (vs TACE)
OS promising
Toxicity acceptable
Systemic+TACE as SOC may be close to be a reality!! (2nd +ve study EMERALD-1)”
“Meeting with the best of the best oncology colleagues in the universe.
Thank you to ESMO for bringing us all together. It takes a global village.”
“Dr. Benjamin Besse presents data from ARROS-1 study of NVL-520 (zidesamtinib) in ROS1 NSCLC. RP2D established at 100mg daily. Rationally designed drug with high CNS efficacy and avoiding TRK will help reduce toxicity.”
“Long term survival with neoadjuvant ICI in melanoma, pooled data from INMC presented by Georgina Long. Combo IO with highest rates of MPR and 78% EFS at 3 years. 3y RFS EXCELLENT 94% for those who have MPR. MPR strongly predicts 3y OS.”
“Outstanding talk from Silke Gillessen elegantly presenting PEACE-3 phase 3 trials first results. Adding 6 cycles of Ra223 to enzalutamide as first-line therapy for mCRPC showed significant rPFS improvement + significant OS benefit.”
“What a great network party.
Thanks for having us ESMO pecially.”
“Huge congrats to Pedro Barata who drove this important analysis of SWOG 1500, published just ahead of ESMO24 in Journal of Clinical Oncology.
Lots of dialogue here in Barcelona around management of non clear kidney cancer; I think this paper and data from SUNNIFORECAST are impt parts of the dialogue.”
“Presidential Session ESMO24.
PEACE-3: Enza+ Ra223 vs Senza
Speaker: Silke Gillessen
- mPFS 19.4 vs 16.4m HR 0.69
- TTT HR 0.57
G3 28% combo vs 19% Enza alone Discussed by Dr. Fizazi.”
“Honored to have chaired a symposium on bladder and prostate cancer at ESMO24. Huge thanks to my wonderful co-chair Alison Birtle, all the speakers, Elena Verzoni and the numerous participants. It was both informative and fun!”
“New SOC for high-risk locally advanced cervical cancer (LACC)?
The phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study shows that the addition of pembro to CCRT leads to a significant and clinically meaningful improvement in OS with a manageable safety profile!”
“Presidential for Silke Gillessen.
Radium223 + enza vs enza alone shows a PFS and OS advantage in metastatic CRPC. PEACE3 is an investigator trial and rejuvenates radium-223 in prostate cancer. 0.69 HR for PFS and OS!!!”
“Amazing and clear overview of T cell engagers in Pca and future therapeutic strategies by the one and only Neeraj Agarwal.
Finally a lot of excitement with IO in Pca!”
“At last – a new treatment for patients with advanced anal SCC.
Pod1um-303 shows 6m mOS for anti-PD-1 + chemo.
ESMO24 Presidential.”
“Over 40,000 members are part of the ESMO family. Thank you to all for believing in this society. Special thanks go to the presidents, the executive and council members and the membership committee.”
“POD1UM-303/InterAACT 2
Inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal
Randomized: Carbo/Taxol vs. Carbo/Taxol + retifanlimab
Addition of retifanlimab associated with:
OS 29 vs 23 m
PFS 9 vs 7 m
New SOC!!”
“At ESMO24 Fedro Peccatori presenting first evidences about safety of breastfeeding in pts in POSITIVE trial Breastfeeding did not increase BC events with 2y cumulative incidence of 3.6% in breastfeeding vs 3.1% in non-breastfeeding group (HR: 1.12, CI 0.28 – 4.5).”
“PEACE-3 at ESMO24 Practice changing for 1L mCRPC patients who didn’t use ARPI in mCSPC
1L mCRPC patients with bone metastases
1:1 to ENZ vs ENZ-RAD (6 cycles)
Primary endpoint: rPFS
446 men, FU 42.2 months
HR for rPFS 0.69 (p=0.0009)
HR for OS 0.69 (p=0.0031)
Bone-protecting agent is mandatory!!!
More adverse grade 3 or greater AE (19 vs 28%).”
“Olverembatinib, in ESMO, showed benefits for GIST patients with SDH deficiency, interesting results for an orphan disease.
A new opportunity César Serrano García?”
“Discusssnt Stephen Liu; ADRIATIC new global SOC; half offered PCI. Benefit to be evaluated in ongoing trials carbo seems better than cis but confounders.
Re Bay> large study? Or small biomarker study.”
“Jordi Remon elegantly presenting PECATI phase 2 lenvatinib plus pembro in pretreated B3-thymoma and thymic carcinoma. Primary endpoint met 5-mo PFS 88%. Promising 12-mo OS 85%. Higher dose intensity associated with better outcomes. Manageable safety BUT irAE 14%.”
“The best way to start ESMO2024 for neuroendocrine community! Amazing session, brilliant speakers, vibrant discussions. Lovely friends and colleagues and more
- CMV-118 in progressive NET
- CABONEN in low G3 NEN
- NETTER-2 and new insights
- Carcinoid heart disease and NET.”
“BR31 by Dr. Glen Goss, a herculean academic effort examining adjuvant durvalumab for resected lung cancer sadly negative, pushes the narrative even more toward neoadj/periop, the results by PD-L1 suggest this was a study destined to be negative.”
“Radiotherapy does not add to mFOLFIRINOX in borderline resectable Pancreatic Cancer – results for PRODIGE-44 ESMO24.
Good news for patients with PDAC – mFOLFIRINOX had outcomes (mOS 32.8m, 47.9m OS if resected).
Results confirm ESMO guidelines recommendations.”
“Results from TiNivo2 are out both ESMO24 and The Lancet! Another phase 3 trial to assess the efficacy of immunotherapy rechallenge, comparing tivozanib + nivolumab vs. tivozanib monotherapy in patients with RCC following an immune checkpoint inhibitor (ICI). (link)
Prior tivozanib trial (TIVO-3) showed an improvement in progression free survival (PFS) with tivozanib compared with sorafenib (HR = 0.55; p=0.028) in the subgroup (26%) that received previous ICI. (link)
CONTACT-03 trial (atezo + cabo to cabo-monotherapy), the first randomized phase 3 evidence of ICI rechallenge in mRCC, revealed negative results, suggesting that ICI rechallenge should be discouraged in pts with mRCC. (link)
TiNivo-2 is multicenter, randomized, open-label, phase 3 trial
Inclusion criteria were:
- Metastatic ccRCC
- ECOG PS: 0 or 1
- Prior progression on 1-2 regimens (one ICI), following ≥ 6 weeks of ICI
- Time from prior line discontinuation to randomization ≤ 6 months
Patients were randomized 1:1 to tivozanib (0.89 mg/day, orally) + nivolumab (480 mg every 4 weeks, IV) or tivozanib (1.34 mg/day, orally)
- 1ary endpoint: PFS (central review)
- 2ary endpoint: OS/ORR
343 pts were assigned to tivozanib-nivolumab (171) or tivozanib monotherapy (172).
Time from randomization to data cutoff was 12.0 months.
Baseline characteristics:
No PFS benefit was observed with Tivo+Nivo vs Tivo only
At 12 months of follow-up, PFS was 5.7 months (95% CI 4.0–7.4) in the Tivo+Nivo group and 7.4 months (5.6–9.2) in
Tivo-monotherapy group (HR = 1.10 (95% CI 0.84–1.43; p=0.49)).
Predefined analyzes per strata were consistent with the primary analysis, whether patients had received an ICI as part of their most recent therapy or not, and whether the study drug was 2nd or 3rdline therapy.
Median OS: 17.7 m (95% CI 15.1–not reached [NR]) in the Tivo+Nivo group vs. 22.1 m (15.2–NR) in the Tivo-monotherapy group (HR:1.0).
ORR: 19% (95% CI 13.7-26.0) in the Tivo+Nivo group vs. 20% (14.1–26.5) in the Tivo-monotherapy group.
Grade 3+ adverse events (AEs) were ~60% in both treatment arms.
Most common grade 3+ AEs was hypertension, reported equally in both groups
at 75 (22%).
AEs led to withdrawal in 16% and 19% of pts on Tivo+Nivo and Tivo-montherapy, respectively.
In conclusion, the addition of PD-1 inhibitor nivolumab to tivozanib did not result in improved clinical outcomes in patients with mRCC whose disease progressed on or after prior ICI treatment. This trial confirms and expands key conclusions from CONTACT-03 and suggests that ICI rechallenge should be generally discouraged regardless of treatment sequence.
Huge thanks to all the investigators who made this trial possible, to AVEO Oncology, the sponsor, and mostly to our patients and their families, to whom we dedicate all our efforts!”
“Congrats Piotr Rutkowski and team for presenting their investigator initiated AXAGIST study on axitinib and avelumab in refractory GISTs. Disease control rate of up to 70% in this hard to treat group!”
“Terrific ending for ESMO24 day one, getting to connect, chat, hug, celebrate with some of the kindest and strongest voices in oncology— thank you OncoDaily for one more superb party!”
“Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer. (link)
KRASG12R tumors are associated with decreased distant recurrence and improved survival as compared to KRASG12D.”
“DESTINY breast 12
- 12 month PFS overall, similiar w stable and active brain mets 62.9% & 59.6%
- median PFS = 17.3 mon
- CNS ORR = 71.7%
- 12-month OS was maintained in patients with BMs (90.3%) and without BMs (90.6%).”
“Belzutifan vs everolimus showed RR and PFS but not significant OS ESMO2024 . Despite this lack of OS belzutifan looks as good as sequencing other VEGF TKI therapy, but with a nice toxicity signal. The ESMO guidelines group gave it a strong recommendation especially 3rd line.”
“Destiny-Breast12: One of the highlights at ESMO24 presented by Nancy Lin. Practice changing data for mBC patients with HER+ disease and brain metastases. So finally patients with active brain metastases are being included in trials.”
“End of day 1 ESMO24 with Paolo Tarantino GRASP Philippe Aftimos MD and many friends from The Multinational Association of Supportive Care in Cancer (MASCC) and Alejandro R. cc OncoDaily.”
“ESMO – YO Mentorship Session.
Great opportunity to sit down and talk with young oncologists all over the world interested in a career in clinical trial design and conduct, with the expert advise and counsel of a field giant such as Giuseppe Curigliano.
Thank you ESMO – European Society for Medical Oncology for this amazing opportunity.”
“Can’t wait to see all photos of the OncoDaily beach party!
Thanks for having us, such a great network event during ESMO24 .
What has climate change to do with Oncology?
Do not miss Dr. Amy Booth from University of Oxford tomorrow Saturday at 10am Sala Tarragona!”
“Amazing overview of non-clear cell kidney cancer by Pedro Barata at ESMO24. Spanning papillary, chromophobe, collecting duct, RMC and multiple other subtypes, he eloquently provides perspective on optimal management based on available data for each disease state. The bottom line: we need more dedicated trials in this space!”
“New 1L SoC in metastatic anal cancer : Retifanlimab + CarboTax vs CarboTax:
- PFS: 9.3 vs 7.4 mo
- OS trend: 23 vs 29 mo
- ORR: 48% vs 36%
Congrats Sheela Rao et al.
Just missed participation of countries where #analcancer is frequent (Brazil, South Africa).”
“Masterful discussion of ILD with TDXd by Dr. Pat LoRusso.
HER ‘low’ expression in lungs – likely why worse with TDXd than other ADC targets.
Ethnicities such as Japanese at higher risk.
Prior ILD, hepatic and renal impairment all risk factors.”
“ESMO presidential dinner ESMO President Andres Cervantes‘s provided the stats on the ESMO24 meeting: record breaking number of abstract submission (>5000), invited speakers (>600), and membership >40k. Amazing job by various committees to make it so successful. Congrats!”
“Breaking news (practice changing) from ESMO24.
Tom Powles presents the 1st results of the ph3 Niagara trial of cisplatin + gemcitabine +|- durvalumab in MIBC bladder cancer.
Significant improvement in DFS (HR 0.68) and OS (HR 0.75) with durvalumab.”
The NIAGARA trial (NCT03732677) is a phase III, randomized, open-label, multicenter, international study set to enroll approximately 1,050 patients with muscle-invasive bladder cancer (MIBC).
Participants, prior to undergoing radical cystectomy, will be randomly assigned in a 1:1 ratio to receive either durvalumab combined with gemcitabine and cisplatin (Arm 1) or gemcitabine and cisplatin alone (Arm 2).
“KN522 OS data 5 yrs after the initial pCR presentation
75 months of f/u for chemo +/ pembro I stage II and III TNBC
- EFS is stable from before with 9% improvement with pembro
- OS improved by 5% (81.7-> 86.6%).”
“PRESIDENTIAL Session ESMO24
NIAGARA: Durva+CisGemx4>IQ->Dura 8 cycles
cT2-4N1/0M0 #UC
- EFS 67.8 vs 59.8% 2yrs HR 0.68
- OS 82.2vs 75.2% 2yrs HR 0.75
- High PDL1expr
- NEW SoC MIBC.”
” ‘What can we do to help individuals, systems, and societies?’ The question to kickoff the ESMO Resilience Task Force Special Open Forum from chair Dr. Banerjee on Sustaining the oncology workforce and tackling burnout in oncology and medicine as a whole!
Looking forward to the insights of Matteo Lambertini, Jon Lim, Jean-Yves Blay, Konstantinos Kamposioras and Maria Elena Elez Fernandez.”
“SPLASH at ESMO24.
Phase III trial for mCRPC patients PSMA+, after ARPI, in the pre-chemotherapy setting
- 2:1 to Lu-PSMA-I&T (4 cycles) vs alternative ARPI
- Primary endpoint: rPFS
- 412 men, crossover was 84.6%
- HR for rPFS 0.71 (p=0.0088)
- No OS benefit is this first interim analysis
- TEAEs were lover with Lu-PSMA (30.1 vs 36.9%).”
“Disitimab vedotin + Pembrolizumab in 1L treatment for mUC presented by Matt Galsky. Thrilled to have participated in this trial University Hospitals, Case Comp Cancer Ctr.
- HER2 is important target even in HER2 low patient
- 75.0% ORR, 35% CR
- DV + P vs DV randomization ongoing.”
“Hot off the press.
Read my comments on the ESMO – European Society for Medical Oncology Presidential Symposium Precision Oncology trials and DRUP-like trials presented at ESMO24:
Drug rediscovery trials facilitate access to Precision Oncology and highlight the importance of integrating comprehensive Genomic Profiling into clinical practice across a broad range of tumour types.”
“What a great emotion to present the the Rome trial results at ESMO 24 Presidential Session!!!!!
One of the greatest of my life!!! Precision medicine is growing, and as a friend of mine says : it’s becoming an adult Benedikt Westphalen !! thanks a lot to my great mentor Paolo Marchetti, to Giuseppe Curigliano, all Rome trial centers and to our dream team!!!!”
“An amazing ESMO-SIOG session on multidisciplinary approach to management of older adults with cancer today at ESMO24.
Had the privilege to co-chair this with Boulahssass Rabia and work with Etienne Brain, Laura Biganzoli and Axel S. Merseburger in coming up with 2 interesting cases in prostate and breast cancer highlighting importance of MDTs in personalizing care for our older adults with advanced cancer based on the latest evidence.
Looking forward to more data in this space at the SIOG – International Society of Geriatric Oncology annual meeting in Montreal next month.
Many thanks to ESMO – European Society for Medical Oncology for organising this special sesion in this years meeting.”
“An exciting experience to attend ESMO – European Society for Medical Oncology with 5000 visitors from all over the world. Barcelona delivered warm weather, and the congress a networking and learning environment.
A special thank you to my friends in the Cancer Mission Board who were there, and for the opportunity to present the ECPC a coming portal for patients for sharing data and communicate with others in the Cancer area.”
“Barcelona is almost over – was nice to see the ideas and plans of our scientific sarcoma track subcommittee come to fruition. It was a good collaboration as always, led by track chair Bernd Kasper.
Also happy to give a lecture in the multidisciplinary session discussing response after neo-adjuvant treatment of soft tissue sarcoma and the impact on surgery.
Together, we, as the international sarcoma community, try to constantly improve our multidisciplinary treatment strategies since we want to do better for our patients and give them a better chance and more hope.”
“SIOPE is delighted to attend the ESMO Congress in Barcelona.
It is very important for us to be here and foster our collaboration, especially in the AYA field.”
SIOG:
“The ESMO/SIOG working group hosted a special session today at ESMO24 highlighting the holistic approach to cancer care for older adults:
‘Working together in the era of personalized care for older adults with cancer.’ ”
“It was such a great honor to talk about ‘Tumor-Agnostic Biomarker Driven Drug development: How and How often?’ at the special joint session of ASCO and ESMO meeting.
Grateful to our beloved ASCO President Robin Zon, and amazing ESMO President Andres Cervantes for the invite to the talk & their vision in putting this amazing session together.“
“Just presented at the ESMO24 Presidential Symposium III by the king Andrea Botticelli, a massive Italian precision medicine effort….fantastic presentation my friend and super important data!!!”
45 Posts Not To Miss From ESMO24 Day 1
43 Posts Not To Miss From ESMO24 Day 2
40 Posts Not To Miss From ESMO24 Day 3
34 Posts Not to Miss From ESMO24 Day 4
More posts featuring ESMO24 on oncodaily.com
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023